Bayer Oy

Bayer Schering Pharma Ag

Upm-kymmene Corporation

Bayer Shering Pharma Oy

Bayer Intellectual Property Gmbh

Harri Jukarainen

Ilkka Jutila

Ulla Calvo Alonso

David Whitaker

Heikki Lyytikäinen

Pirjo Kortesuo

Hannu Nikander

Pirjo Inki

Juha Lehtinen

Eeva Lukkari-Lax

Joachim Moede

Pirjo Sallinen

Andrew Macleod

Michael Noble

Michael Nobel

Taina Tjäder

Taina Träder

Ulrike Fuhrmann

Bernhard Lindenthal

Jyrki Pihlaja

Ina Gröticke

Manja Ahola

Satu Kleemola

Tero Parkatti

Tuula Valo

Bernd Duesterberg

Christian Wamprecht

Markus Nuopponen

Antti Laukkanen

Wolfgang Kaufhold

Lauri Paasonen

Christine Talling

Anne Meriluoto

Timo Laaksonen

Faisal Shafiq

Svante Holmberg

Jouni Hirvonen

Ruzica Kolakovic

Jukka Rissanen

Taina Tjaeder

Emilia Tiitinen

Rudolf Knauthe

Prijo Kortesuo

Leena Peltonen

Jenny Hollaender

Anu-Liisa Honka

Heinz Schmitz

Arto Pakkalin

Henriikka Korolainen

Heikki Lyytikaeinen

The present invention relates to an inserter for an intrauterine system comprising a handle (), and an insertion tube () having a first end and a second end, and being arranged in connection with the handle. The inserter is characterized in that the first end of the insertion tube () comprises at least one frame slot for receiving a frame of the intrauterine system. The invention also relates to a kit comprising an inserter according to the present invention and an intrauterine system, wherein the intrauterine system () comprises a therapeutic component () and a continuous, closed frame (), the therapeutic component () being connected to the frame () at least one point, and therapeutic component () of the intrauterine system () is at least mainly arranged inside the first end of the insertion tube () and the frame () of the intrauterine system () is at least mainly arranged outside the first end of the insertion tube ().

Inserter

An injectable pharmaceutical formulation includes nanofibrillar cellulose hydrogel wherein the content of nanofibrillar cellulose in the pharmaceutical formulation is the range of 1-8% (w/w), and pharmaceutical compound. The injectable pharmaceutical formulation can provide a sustained release of a pharmaceutical compound in a subject. Use of nanofibrillar cellulose for preparing the injectable pharmaceutical formulation is also disclosed.

Injectable pharmaceutical formulation

The present invention relates to an inserter for an intrauterine system, comprising a handle () having a longitudinal opening () at its first end, said opening () having a longitudinal axis parallel to the longitudinal axis of the inserter, a first end () and a second end (), a movable slider () arranged in said longitudinal opening () and having a first end () and a second end (), a plunger () attached to the handle () and having a longitudinal axis, and an insertion tube () having a first end, a second end and a longitudinal axis essentially parallel to the longitudinal axis of the plunger (), the insertion tube () being, along said longitudinal axis, movably arranged around the plunger (). The invention is characterised in that it further comprises a flange () arranged on the insertion tube () at its first end, and means for locking the slider () into a position showing the correct insertion depth for the intrauterine system, said means being adjustable with respect to the opening () of the handle.

A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.

Drug delivery system for sustained delivery of bioactive agents

The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.

Intrauterine delivery system for contraception

The present invention provides a novel drug delivery system for the controlled release of therapeutically active substances at a predetermined, essentially constant release rate over a prolonged period of time. The delivery system comprises at least one core comprising said therapeutically active substance(s), at least one membrane encasing the core and an intermediary layer of a substantially inert material, wherein the intermediary layer is applied between the core and the membrane or between two membrane layers.

Drug delivery system

The present invention relates to novel intrauterine systems and to methods for manufacturing these systems. An intrauterine system according to the invention comprises a reservoir and a continuous, closed and flexible frame. The frame comprises a thermoplastic polyurethane elastomer made of a polycarbonate diol, 1,6-hexamethylenediisocyanate, and a chain extender.

Intrauterine system

The present invention relates to an inserter for an intrauterine system, comprising a handle () having a longitudinal opening () at its first end, said opening () having a longitudinal axis parallel to the longitudinal axis of the inserter, a first end () and a second end (), a movable slider () arranged in said longitudinal opening () and having a first end () and a second end (), a plunger () attached to the handle () and having a longitudinal axis, and an insertion tube () having a first end, a second end and a longitudinal axis essentially parallel to the longitudinal axis of the plunger (), the insertion tube () being, along said longitudinal axis, movably arranged around the plunger (). The invention is characterized in that it further comprises a flange () arranged on the insertion tube () at its first end, and means for locking the slider () into a position showing the correct insertion depth for the intrauterine system, said means being adjustable with respect to the opening () of the handle.

The present invention relates to the use of tocopherol as a co-catalyst in the ring opening polymerisation of cyclic siloxanes. The present invention further relates to a method for manufacturing hydrophilic polysiloxanes, wherein a hydrido-containing cyclic siloxane is reacted with a hydrophilic molecule comprising a carbon-carbon double bond, having the general formula (I) HC&#x2550;CH&#x2014;(CHR)&#x2014;O&#x2014;(CHRCRR)Ror (II) HC&#x2550;CH&#x2014;(CHR)&#x2014;R, wherein n is an integer from 0 to 4, m is an integer from 0 to 5, R, R, R, Rand Rare each independently hydrogen or a Cto Calkyl, Ris a saturated cyclic hydrocarbon containing carbonyl group, in the presence of a first catalyst to obtain a monomer, and polymerising said monomer in the presence of a second catalyst and tocopherol as a co-catalyst.

Use of tocopherol

Intrauterine device

Growing community of inventors

Kuusisto, Finland

Harri Jukarainen